X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (467) 467
Newspaper Article (25) 25
Publication (17) 17
Book Review (10) 10
Book / eBook (7) 7
Book Chapter (4) 4
Dissertation (2) 2
Conference Proceeding (1) 1
Kit (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (173) 173
female (158) 158
oncology (144) 144
breast neoplasms - drug therapy (127) 127
middle aged (94) 94
breast cancer (93) 93
breast neoplasms - pathology (93) 93
index medicus (93) 93
adult (85) 85
aged (76) 76
chemotherapy (72) 72
antineoplastic combined chemotherapy protocols - therapeutic use (67) 67
treatment outcome (55) 55
aged, 80 and over (41) 41
cancer (38) 38
breast neoplasms - mortality (37) 37
metastasis (36) 36
hematology, oncology and palliative medicine (35) 35
antineoplastic agents - therapeutic use (34) 34
disease-free survival (34) 34
neoplasm metastasis (33) 33
neoplasm staging (32) 32
paclitaxel (32) 32
trastuzumab (32) 32
care and treatment (31) 31
deoxycytidine - analogs & derivatives (31) 31
therapy (31) 31
capecitabine (30) 30
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
breast neoplasms - metabolism (26) 26
clinical trials (26) 26
docetaxel (25) 25
obstetrics and gynecology (25) 25
chemotherapy, adjuvant (24) 24
deoxycytidine - administration & dosage (24) 24
medicine & public health (24) 24
breast neoplasms - genetics (23) 23
metastatic breast cancer (23) 23
paclitaxel - administration & dosage (23) 23
survival (23) 23
drug administration schedule (22) 22
prognosis (21) 21
quality of life (20) 20
tumors (20) 20
antineoplastic agents - adverse effects (19) 19
doxorubicin - administration & dosage (19) 19
receptor, erbb-2 - metabolism (19) 19
clinical trials as topic (18) 18
metastases (18) 18
patients (18) 18
research (18) 18
trial (18) 18
breast neoplasms - therapy (17) 17
cancer therapies (17) 17
doxorubicin (17) 17
multicenter (17) 17
anthracyclines (16) 16
fluorouracil - analogs & derivatives (16) 16
phase-ii (16) 16
tamoxifen (16) 16
follow-up studies (15) 15
kaplan-meier estimate (15) 15
neutropenia (15) 15
survival analysis (15) 15
survival rate (15) 15
anthracycline (14) 14
cyclophosphamide - administration & dosage (14) 14
gemcitabine (14) 14
male (14) 14
medical research (14) 14
prospective studies (14) 14
risk factors (14) 14
taxoids - administration & dosage (14) 14
women (14) 14
animals (13) 13
combination (13) 13
paclitaxel - adverse effects (13) 13
surgery (13) 13
antimetabolites, antineoplastic - therapeutic use (12) 12
antineoplastic agents, hormonal - therapeutic use (12) 12
article (12) 12
bevacizumab (12) 12
epidermal growth factor (12) 12
postmenopausal women (12) 12
taxoids - therapeutic use (12) 12
time factors (12) 12
toxicity (12) 12
analysis (11) 11
antibodies, monoclonal, humanized (11) 11
cancer research (11) 11
clinical trials, phase iii as topic (11) 11
combined modality therapy (11) 11
cyclophosphamide (11) 11
deoxycytidine - therapeutic use (11) 11
drug therapy (11) 11
erbb-2 protein (11) 11
expression (11) 11
health aspects (11) 11
her2 (11) 11
infusions, intravenous (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Baylor University Medical Center Proceedings, ISSN 0899-8280, 04/2004, Volume 17, Issue 2, pp. 168 - 184
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2011, Volume 364, Issue 3, pp. 205 - 214
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9769, pp. 914 - 923
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 9, pp. 884 - 890
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit... 
TRIAL | MOLECULAR PORTRAITS | ONCOLOGY | BEVACIZUMAB | SUBTYPES | 2ND-LINE TREATMENT | DOUBLE-BLIND | ABIRATERONE ACETATE | PHASE-II | METASTATIC PROSTATE-CANCER | CHEMOTHERAPY | ORIGINAL REPORTS
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2019, Volume 20, Issue 11, pp. 1587 - 1601
Trilaciclib is an intravenous cell-cycle inhibitor that transiently maintains immune cells and haemopoietic stem and progenitor cells in G1 arrest. By... 
Journal Article
1991, 2 cassettes
Book
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 23, pp. 2647 - 2655
Journal Article
Journal Article
Journal Article